Two Ulcerative Colitis Biologics: Same Clinical Difference?
While infliximab (Remicade) and vedolizumab (Entyvio) were comparable for clinical remission in previously biologic-naive ulcerative colitis patients, infliximab was more likely to result in corticosteroid-free clinical remission as well as endoscopic remission, a post-hoc analysis found. At 1 year, a similar percentage of ulcerative colitis patients reached clinical remission from infliximab and vedolizumab (39.9% vs […]